Canada· CA-DIN-02403374
ROSIGLITAZONE
A rosiglitazone product containing rosiglitazone (rosiglitazone maleate), registered in Canada by AA PHARMA INC. The same ATC class is registered in 5 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Rosiglitazone is registered in 5 of 19 countries.
Countries holding a registration under ATC A10BG02 (rosiglitazone), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 2 of them publish a price we can compare per daily dose
Rosiglitazone · ATC A10BG02
5 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Finlandprice
- United Kingdom
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- ROSIGLITAZONE (ROSIGLITAZONE MALEATE)
- Manufacturer
- AA PHARMA INC
- Country
- Canada (CA)
- ATC code
- A10BG02
- ATC class
- Rosiglitazone
- Defined daily dose
- 6 mg, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
703 interactions on record for rosiglitazone.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rosiglitazone · interactions on record
703 records
- 8 severe
- 301 moderate
- 42 minor
- 352 info
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rosiglitazone in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/90bae98d-b151-4a6e-a740-926bd8f4c89b GET /v1/drugs/90bae98d-b151-4a6e-a740-926bd8f4c89b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02403374",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10BG02",
"schedule": [
"Prescription"
],
"drug_code": "88818",
"strengths": [
"4 MG"
],
"ahfs_class": null,
"substances": [
"ROSIGLITAZONE (ROSIGLITAZONE MALEATE)"
],
"product_categorization": null
}See everything about rosiglitazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.